Florida Cancer Specialists expands radiation oncology care in Sarasota and Manatee counties with new appointment

Why is Florida Cancer Specialists expanding radiation oncology capacity in Sarasota and Manatee counties now?

Florida Cancer Specialists & Research Institute, LLC (FCS), one of the largest independent oncology practices in the United States, has reinforced its presence on Florida’s Gulf Coast by expanding its radiation oncology team in Sarasota and Manatee counties. The statewide practice announced that radiation oncologist Reema Ishteiwy, MD, PhD has joined its Radiation Oncology Center at Sarasota Memorial Hospital’s Brian D. Jellison Cancer Institute. She will work alongside FCS board-certified radiation oncologists, including medical director Kunal Saigal, MD, as well as colleagues Matthew C. Biagioli, MD, MS, and John Bollinger, MD.

The addition underscores FCS’s commitment to scaling capacity in one of the fastest-growing regions of Florida. The population boom along the Gulf Coast has been accompanied by rising demand for advanced oncology services, particularly radiation therapy, which is integral in treating prostate, gynecologic, and other complex cancers. According to the American Cancer Society, Florida continues to report among the highest incidence of cancer diagnoses in the U.S., making timely access to care an urgent priority.

How does Dr. Reema Ishteiwy’s expertise strengthen FCS’s oncology research and treatment programs?

Dr. Ishteiwy’s appointment brings both clinical depth and research expertise. She earned her medical degree and doctorate in molecular and cellular pharmacology from the University of Miami Miller School of Medicine, followed by residency training in radiation oncology at the University of Louisville Medical School. Her clinical research has centered on prostate and gynecologic cancers, with a focus on refining precision radiotherapy techniques that minimize side effects while improving treatment outcomes.

By joining FCS, she integrates into one of the most active private research networks in the country. For decades, FCS has positioned itself as a leader in clinical trials, often serving as a first access point for patients to new cancer drugs before FDA approval. This has made the practice not just a healthcare provider, but also an industry player shaping the pipeline of oncology therapies nationwide.

Industry analysts note that oncology research centers capable of combining clinical treatment with large-scale trial access have become increasingly attractive partners for pharmaceutical companies. In this respect, Dr. Ishteiwy’s expertise in trial-driven radiotherapy research strengthens FCS’s appeal as a strategic partner in the drug development and commercialization process.

What role does Sarasota Memorial Hospital play in delivering next-generation oncology care with FCS?

The partnership between FCS and Sarasota Memorial Hospital’s Brian D. Jellison Cancer Institute is central to the delivery of next-generation cancer care in the region. Assistant Managing Physician David Wenk, MD, emphasized that the collaboration reflects FCS’s strategy of embedding oncology capacity within fast-growing communities. By operating within Sarasota Memorial Hospital, FCS ensures that patients can receive radiation therapy close to home without needing to travel long distances for advanced care.

Medical Director of Radiation Oncology Sachin Kamath, MD, noted that the addition of Dr. Ishteiwy further enhances a team already versed in advanced radiotherapy techniques such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and stereotactic body radiation therapy (SBRT). These technologies allow oncologists to deliver high-dose, highly targeted radiation to tumors while sparing surrounding healthy tissue.

For Sarasota and Manatee counties, the availability of such therapies signals an upgrade in regional oncology infrastructure, moving it closer to parity with major metropolitan hubs such as Miami, Tampa, and Orlando.

Why is Florida Cancer Specialists seen as a national leader in clinical research among private oncology practices?

Over its 40-year history, Florida Cancer Specialists has become a critical testing ground for new oncology drugs and therapies. The practice often serves as the first site where patients gain access to investigational medicines, effectively shaping the trajectory of cancer treatment nationally. The institute’s broad reach — spanning more than 100 locations across Florida — allows clinical trials to enroll diverse patient populations at scale, which is increasingly valued by regulators and drugmakers.

Historically, clinical research in oncology was concentrated in academic medical centers. However, FCS’s model demonstrates how private practices can deliver trial access in community settings. This decentralized model accelerates recruitment and improves real-world data capture. According to industry observers, this approach reflects broader trends in U.S. healthcare toward community-based innovation rather than academic exclusivity.

How does this expansion fit into broader oncology industry and demographic trends in Florida?

Florida remains one of the most demographically significant states for oncology care. Its aging population and rapid in-migration have made it a bellwether for cancer incidence trends nationwide. In Sarasota and Manatee counties, population growth has consistently outpaced state averages, leading to a rise in demand for oncology specialists.

Nationally, the oncology sector has been experiencing consolidation, with large private groups like FCS expanding to meet both demand and cost pressures. Independent practices have increasingly turned to partnerships with hospitals and insurers to maintain scale, secure reimbursement, and fund capital-intensive technologies such as proton therapy machines and AI-driven imaging systems.

In this landscape, FCS’s growth in Sarasota and Manatee can be seen as both defensive and opportunistic: defensive in ensuring that regional demand does not overwhelm existing infrastructure, and opportunistic in capturing new patient inflows before competitors.

What does the expansion mean for patient access, innovation, and long-term healthcare outcomes?

The most immediate impact is expanded patient access. For residents of Sarasota and Manatee counties, the arrival of a new radiation oncologist within the FCS network reduces wait times and broadens the range of therapies available locally. This is critical in cancer treatment, where delays can significantly affect survival rates.

From an innovation perspective, the expansion increases the region’s participation in clinical trials. Patients gain earlier exposure to investigational treatments, pharmaceutical companies gain real-world trial data, and FCS strengthens its position as a trial partner of choice.

Long-term, the presence of highly specialized radiation oncologists within community settings could reshape local healthcare outcomes. By offering advanced therapies without requiring patients to travel to urban academic centers, FCS ensures that smaller counties do not lag in access to breakthrough treatments.

What are the financial and institutional implications of FCS’s continued expansion in Florida?

While FCS is privately held and not listed on public exchanges, its scale and trial activity make it a bellwether for investor sentiment toward oncology infrastructure. Institutional capital has increasingly flowed into cancer treatment platforms, ranging from hospital-linked expansion projects to private equity-backed oncology groups.

The expansion in Sarasota and Manatee counties fits into this narrative. It demonstrates that demand for oncology services remains resilient even as other areas of healthcare face margin pressures. For institutions tracking private oncology performance, FCS serves as a proxy for the sector’s attractiveness. Analysts suggest that if FCS were ever to consider a capital markets event such as an IPO or strategic partnership, its trial access advantage and statewide footprint would make it highly competitive.

In strengthening its radiation oncology capacity in Sarasota and Manatee counties, Florida Cancer Specialists & Research Institute is not only responding to demographic realities but also reinforcing its dual identity as both a treatment provider and research leader. The integration of Dr. Reema Ishteiwy into its Gulf Coast practice represents more than a personnel addition — it is a reflection of the institute’s strategy of combining cutting-edge science, community access, and institutional credibility in one of the most consequential healthcare markets in the country.